How long has Wegovy been studied, and what does the evidence show?

Step 1: the research timeline, in sequence

Semaglutide did not arrive as a weight-loss medicine from nowhere. Novo Nordisk had been studying it for type 2 diabetes since the early 2010s, and those Ozempic-era trials quietly built a pharmacological profile over hundreds of thousands of person-weeks of exposure. By 2016, researchers were already exploring what the higher doses used in weight management might do for people without diabetes.

The formal STEP (Semaglutide Treatment Effect in People with obesity) programme launched in 2018 and eventually comprised four main trials. STEP 1 is the headline study: 1,961 adults with obesity or overweight plus a weight-related condition, randomised to 2.4 mg semaglutide or placebo, followed for 68 weeks. Published results showed an average weight reduction of roughly 15%, compared with around 2.4% in the placebo group. Those figures come directly from the STEP 1 paper in the New England Journal of Medicine. STEP 2 looked at people with type 2 diabetes; STEP 3 at intensive behavioural support alongside the injection; STEP 4 at what happens when treatment is stopped. Taken together, they represent a research investment of several years before any approval was granted.

The NHS semaglutide medicine page reflects the accumulated evidence from these trials, noting that Wegovy is licensed for long-term weight management alongside reduced-calorie eating and increased physical activity.

What longer follow-up has revealed

One misconception worth gently setting aside is that the research stopped after the initial approval. It did not. STEP 1 included a 20-week off-treatment observation period, and data from that extension showed that much of the weight lost returned when the medicine was discontinued. That finding was not a failure of the research; it was the research doing its job, clarifying that semaglutide works as a long-term treatment rather than a short course.

Beyond the STEP programme, the SELECT trial examined cardiovascular outcomes in roughly 17,600 adults with established cardiovascular disease and overweight or obesity. Run over a mean of about 34 months, it found a meaningful reduction in major cardiovascular events in the semaglutide group. The MHRA's approval of Wegovy for a cardiovascular risk-reduction indication in the UK followed, and in July 2026 conditional approval was granted for a liver disease (MASH) indication, reflecting how the evidence base for semaglutide continues to grow well beyond weight loss alone. You can read more about the full clinical picture on our Wegovy study results page.

The most recent regulatory development was the April 2026 approval of a single-dose 7.2 mg pen, supported by trial data showing approximately 20.7% average weight loss over 72 weeks at the higher dose, narrowing the gap with tirzepatide results considerably.

How the evidence translates into UK prescribing today

All of this research feeds directly into the NICE appraisal that shapes who can access Wegovy on the NHS. NICE's recommendation (TA875) sets the framework: weight management in adults with a BMI of 35 or above and at least one weight-related condition, within a specialist service, for a maximum of two years. Lower BMI thresholds apply for certain ethnic backgrounds under UK guidance. The criteria are deliberately drawn from the populations studied in the STEP trials, which is why eligibility and evidence are so closely linked.

For people who do not meet NHS criteria, or who would rather not wait, private prescribing through a regulated pharmacy is the legal alternative. The same clinical assessment applies: a prescriber reviews your health history, BMI, and any conditions before making a decision. If you are curious about how your own circumstances fit, our guide to getting Wegovy through a legitimate UK route covers the options clearly.

The research record also shapes how a prescriber monitors progress. NICE recommends reviewing treatment at six months: if weight loss at the highest tolerated dose has not reached 5%, the clinical case for continuing is reconsidered. That threshold comes directly from the trial data and is applied consistently.

What we still do not know, and why that matters

Honesty about gaps is part of reading the evidence properly. Most trial participants were followed for 68 to 72 weeks, just over a year. If you are curious about how long Wegovy has been out as an approved medicine, that context helps explain why extended observational data beyond two to three years remain limited for the weight-management indication, though the cardiovascular and diabetes programmes add some longer-term safety context. Paediatric data are limited, which is why Wegovy is not licensed for under-18s in the UK. Pregnancy and breastfeeding data are absent by design, meaning the medicine is not recommended for anyone who is pregnant, trying to conceive, or breastfeeding.

For a broader picture of how long semaglutides have been in clinical use, including the diabetes history that preceded Wegovy, the full timeline puts the evidence base in context. If you want to understand how long Wegovy has been around and how that shapes confidence in the current prescribing framework, our dedicated page traces the approval history in full. And if you are wondering how quickly the medicine tends to produce results once treatment begins, our page on how long Wegovy takes to work walks through what the trials show week by week. Check your eligibility for treatment through a free consultation with our prescribers, a real clinician reads your answers the same day.